Small Cell Lung Cancer Clinical Trials in Grand Rapids, Michigan

4 studies are recruiting for small cell lung cancer in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

    The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small…

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan
    Locations
    9 in total
    Run by
    Amgen

    See if you can join NCT07778316 on ClinicalTrials.gov

  2. A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activi…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955, Grand Rapids, Michigan
    Locations
    63 in total
    Run by
    AbbVie

    See if you can join NCT07365241 on ClinicalTrials.gov

  3. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Midwest, Grand Rapids, Michigan
    Locations
    12 in total
    Run by
    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

  4. A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

    This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Midwest, Grand Rapids, Michigan
    Locations
    13 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07174583 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.